The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor.
The atypical beta3-adrenergic receptor (AR) agonist CGP-12177 has been used to define a novel atypical beta-AR subtype, the putative beta4-AR. Recent evaluation of recombinant beta-AR subtypes and beta-AR-deficient mice, however, has established the identity of the pharmacological beta4-AR as a novel state of the beta1-AR protein. The ability of aryloxypropanolamine ligands like CGP-12177 to independently interact with agonist and antagonist states of the beta1-AR has important implications regarding receptor classification and the potential development of tissue-specific beta-AR agonists.
Granneman
J G
JG
Cellular and Clinical Neurobiology Program, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 2309 Scott Hall, Detroit, Michigan 48201, USA. jgranne@med.wayne.edu
D000818:Animals; D006801:Humans; D020033:Protein Isoforms / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000145:classification / Q000502:physiology*; D013678:Technology, Pharmaceutical
D020033:Protein Isoforms; D011943:Receptors, Adrenergic, beta